Question 132: QSR vs QMSR
Posted by むらりん · 2026-10-18 11:09:01 (UTC)
- Target jurisdiction
- United States
- Applicable regulations or standards
- QMSR
- Reference date
- 2026-10-18
Public question
Sign in to download a Word document (first 3 questions free).
AI-generated answer
QSR vs. QMSR — What Actually Changed in 21 CFR Part 820
Jurisdiction covered: United States (U.S. FDA medical device quality system requirements, 21 CFR Part 820). Information current as of: 18 October 2026.
If you need the equivalent comparison for another jurisdiction — for example the EU (MDR 2017/745 / IVDR 2017/746 with ISO 13485 certification), Japan (the MHLW QMS Ordinance), or an Asian market — please say so, and we will address that separately. We do not assume a jurisdiction based on the language in which a question is asked.
Conclusion (short version)
- "QSR" (Quality System Regulation) is the common name for the older version of 21 CFR Part 820, which applied until 1 February 2026. It was a self-contained, FDA-drafted rule (design controls, DMR/DHR/DHF, CAPA, and so on).
- "QMSR" (Quality Management System Regulation) is the current 21 CFR Part 820, as amended. Part 820 itself did not disappear — it was rewritten and renamed. It incorporates ISO 13485:2016 by reference and keeps/adds a limited set of FDA-specific requirements.
- The amending rule — Medical Devices; Quality System Regulation Amendments, FDA final rule, 89 FR 7496, published 2 February 2024, Docket No. FDA-2021-N-0477 — became effective 2 February 2026.
- Harmonized ≠ identical. Conformity to ISO 13485:2016 alone is not the same as compliance with Part 820, and an ISO 13485 certificate does not by itself prove QMSR compliance to FDA. It may be useful supporting evidence, but FDA makes its own compliance determinations and conducts its own inspections against Part 820.
- Records and documents created under the old QSR do not become invalid. What changed is the requirement set you must now demonstrate compliance with: current Part 820 (QMSR).
If you only do three things
- Read the current text of 21 CFR Part 820 on eCFR — the controlling wording, section numbers and paragraph designations are there, not in summaries.
- Run a gap assessment against ISO 13485:2016 (clauses 4–8), because those requirements are now part of U.S. law through incorporation by reference.
- Separately check the FDA-specific requirements, both inside Part 820 (records, labeling and packaging controls, clarification of concepts) and outside it (adverse event reporting, corrections and removals, registration and listing, UDI, electronic records).
1. What each term means
| Term | Meaning |
|---|---|
| QSR | Informal name for the pre-2026 version of 21 CFR Part 820 ("Quality System Regulation"). Final rule published 7 October 1996; effective 1 June 1997. Subparts A–O, roughly §§820.1–820.250. |
| QMSR | The current 21 CFR Part 820 ("Quality Management System Regulation"), in force since 2 February 2026. A much shorter regulation that incorporates ISO 13485:2016 by reference and layers FDA-specific requirements on top. |
| Incorporation by reference (IBR) | A legal technique by which the text of an outside document (here, ISO 13485:2016) is given the force of the regulation. The standard is not reprinted in the Code of Federal Regulations, so you must obtain it from ISO or an authorized distributor. |
Important nuance: incorporation by reference does not mean "ISO 13485 now equals U.S. law in all respects." The incorporated requirements apply as specified in Part 820 and together with Part 820's own provisions. Where the ISO wording and FDA's statutory framework could be read differently, Part 820 contains a clarification provision to resolve the reading in the FDA context.
2. Structure of the current Part 820 (QMSR)
The following reflects the structure of Part 820 as amended. Always confirm section numbers, titles and paragraph designations in the current eCFR text, because regulations can be further amended.
| Section | Subject (summary) |
|---|---|
| §820.1 | Scope and applicability, including exemptions |
| §820.3 | Definitions — a limited set of FDA/FD&C Act-based definitions, with other terms taken from ISO 13485:2016 clause 3 and ISO 9000:2015 |
| §820.5 | Status of the requirements as FDA current good manufacturing practice (CGMP) requirements for devices |
| §820.7 | Incorporation by reference of ISO 13485:2016 (and the related vocabulary standard) |
| §820.10 | The core obligation: establish and maintain a quality management system meeting the requirements of this part, including the incorporated ISO 13485:2016 requirements (the rule's focus is clauses 4 through 8) |
| §820.15 | Clarification of concepts — how certain ISO 13485 terms and concepts are to be read in the FDA/FD&C Act context |
| §820.35 | Control of records — FDA-specific record requirements, including availability of records for FDA inspection and copying, and required content for certain complaint and servicing records (e.g., the unique device identifier, UDI, where applicable) |
| §820.45 | Device labeling and packaging controls — FDA-specific controls where ISO 13485 is less prescriptive |
The point to take away: §820.7 + §820.10 are the gateway to ISO 13485:2016, while §820.15, §820.35 and §820.45 are where FDA-specific obligations live.
3. Side-by-side comparison
| Item | QSR (Part 820, pre-2026) | QMSR (Part 820, current) |
|---|---|---|
| Legal nature | Self-contained FDA-drafted regulation | Regulation that incorporates ISO 13485:2016 by reference, plus FDA-specific provisions |
| Length / layout | Subparts A–O, ~§§820.1–820.250 | Short part (see §2 above) |
| Core obligation | Comply with each FDA-written section | Maintain a QMS meeting Part 820, including the incorporated ISO 13485:2016 requirements, and the FDA-specific sections |
| Source of definitions | FDA definitions in §820.3 | Mainly ISO 13485:2016 clause 3 and ISO 9000:2015, with retained FDA/statutory definitions in §820.3 |
| Risk | Risk analysis explicit mainly in design controls (former §820.30(g)); risk thinking also expected in practice elsewhere | Risk-based approach stated explicitly across the QMS (e.g., ISO 13485:2016 clauses 4.1.2(b), 7.1) |
| FDA-only document names | DMR, DHR, DHF | Not mandated by the regulation; the ISO concepts are the medical device file (4.2.3), production/batch records (7.5.1) and the design and development file (7.3.10) |
| Role of ISO certification | Not applicable | Not a substitute for compliance, and not a substitute for FDA inspection |
| Inspections | QSIT (Quality System Inspection Technique) was the QSR-era approach | FDA has been updating its inspectional approach and compliance program material to match the QMSR structure (see §7) |
4. Indicative concept mapping (not a legal equivalence)
The table below is a learning aid only. In reality one old QSR section can map to several ISO 13485 clauses, and one ISO clause can touch several FDA requirements. Do not use this as a compliance crosswalk without your own analysis.
| Former QSR section (example) | Closest ISO 13485:2016 clause |
|---|---|
| §820.20 Management responsibility | Clause 5 (5.1–5.6, management responsibility) |
| §820.22 Quality audit | 8.2.4 Internal audit |
| §820.25 Personnel | 6.2 Human resources |
| §820.30 Design controls | 7.3 Design and development |
| §820.40 Document controls | 4.2.4 Control of documents |
| §820.50 Purchasing controls | 7.4 Purchasing |
| §820.60 / §820.65 Identification, traceability | 7.5.8 Identification / 7.5.9 Traceability |
| §820.70–§820.75 Production and process controls, process validation | 7.5.1 Control of production and service provision, 7.5.6 Validation of processes |
| §820.80 / §820.86 Receiving, in-process and finished device acceptance; acceptance status | 7.4.3 Verification of purchased product, 8.2.6 Monitoring and measurement of product, 7.5.1 |
| §820.90 Nonconforming product | 8.3 Control of nonconforming product |
| §820.100 CAPA | 8.5.2 Corrective action / 8.5.3 Preventive action |
| §820.120 / §820.130 Labeling, packaging | 7.5.1, plus FDA-specific §820.45 |
| §820.140–§820.170 Handling, storage, distribution, installation | 7.5.11 Preservation of product, 7.5.3 Installation activities |
| §820.180–§820.198 Records, complaint files | 4.2.5 Control of records, 8.2.1 Feedback, 8.2.2 Complaint handling, plus FDA-specific §820.35 |
| §820.200 Servicing | 7.5.4 Servicing activities |
| §820.250 Statistical techniques | 8.1, 8.2.6, 8.4 Analysis of data |
5. What is new, or more explicit, under the QMSR
These come from ISO 13485:2016 and were either absent from the old regulation text or far less explicit in it. They are requirements because Part 820 incorporates the standard, not because FDA wrote them as new FDA sections.
- Quality manual (4.2.2) — a documented description of the QMS, its scope and the interaction of its processes, including justification for any exclusions or non-applicable requirements.
- Medical device file (4.2.3) — for each device type or device family, a file containing or referencing the required documents (specifications, manufacturing, measuring and monitoring, installation, servicing as applicable). How you organize and group these files should be justified by the products and processes concerned; the standard does not dictate a single grouping scheme.
- Validation of software used in the quality management system (4.1.6) — e.g. electronic QMS, document control, training, statistical and automated tools, proportionate to risk. The old QSR addressed software validation in the design and production/process context; the explicit, QMS-wide obligation is clearer here. This is where computerized system validation (CSV) and data integrity practice applies.
- Risk management in product realization (7.1) — risk-based thinking is to be applied across realization processes, not only in the design phase. Many organizations use ISO 14971 as their risk management framework; the standard and the regulation do not oblige every organization to use that specific standard, so the suitability of your chosen method must be justified for your product and regulatory context.
- Feedback and complaint handling (8.2.1, 8.2.2) and reporting to regulatory authorities / advisory notices (8.2.3, 8.3.3) as defined QMS processes feeding improvement.
- Infrastructure, work environment and contamination control (6.3, 6.4), with specific provisions for sterile devices (e.g. 7.5.5, 7.5.7).
- Documented planning, process approach and planning of changes across the QMS (4.1, 5.4, 7.1) — more explicit than the corresponding old QSR wording.
6. What FDA kept as FDA-specific requirements
FDA concluded that some matters were not adequately covered by ISO 13485:2016 and retained them in Part 820:
- Device labeling and packaging controls (§820.45) — e.g. examination of labeling for accuracy before release, controlled labeling storage and control-number traceability. ISO 13485 is considerably less prescriptive here.
- Control of records (§820.35) — including that required records must be available to FDA for inspection and copying, retention expectations, and specified content for certain complaint records and servicing records, such as identification of the device including the UDI where applicable.
- Clarification of concepts (§820.15) — so that ISO terminology is not read more narrowly than the Federal Food, Drug, and Cosmetic Act requires.
One point to verify in the current text: FDA has long taken the position that, during a routine inspection, it does not request the records of management reviews, internal audits and supplier audits, while it may ask management for a written certification that these activities were performed. FDA addressed this subject when adopting the QMSR. Because the exact paragraph designation and wording matter in an inspection, confirm it directly in §820.35 in the current eCFR text before relying on it.
7. Dates and transition
| Date | Event |
|---|---|
| 7 October 1996 | QSR final rule published (effective 1 June 1997) |
| 2 February 2024 | QMSR final rule published — 89 FR 7496, Docket No. FDA-2021-N-0477 |
| 2 February 2026 | QMSR effective date — the amended Part 820 applies |
Key points about the transition:
- The rule provided a two-year lead time between publication and the effective date; the regulation text itself does not create an additional phase-in or a "legacy device" carve-out. Organizations subject to Part 820 were expected to meet the amended requirements from 2 February 2026.
- Effective date and enforcement approach are two different questions. FDA has published explanatory and transition-related material (including FAQ-type documents and educational resources) on its QMSR pages. If you intend to rely on any enforcement-discretion or transition statement, identify the exact document title, number, date and current status on FDA's website — such documents are revised and withdrawn from time to time, and we cannot confirm the current status of any particular one here.
- The same final rule also made conforming amendments to 21 CFR Part 4 (the CGMP requirements for combination products), so that the streamlined approach for single-entity and co-packaged combination products refers to the current Part 820 requirements rather than the former QSR sections. Which Part 4 provisions matter to you depends on your product's constituent parts; check the current Part 4 text rather than assuming a wholesale replacement.
- Scope and exemptions remain in §820.1. Whether and how Part 820 applies depends on your role (finished device manufacturer, specification developer, contract manufacturer, repackager/relabeler, importer), your device classification, and whether design responsibility sits with you. Certain class I devices and certain activities are treated differently. Read §820.1 together with the classification regulation for your device.
8. Inspection and enforcement implications
- FDA inspects and takes action against 21 CFR Part 820. The incorporated ISO 13485:2016 requirements are part of that regulation, so an FDA compliance determination is expressed as a Part 820 matter, with the substance coming from the incorporated requirements plus the FDA-specific sections. How any individual Form FDA 483 observation or Warning Letter is worded varies case by case.
- QSIT (the four-subsystem approach: Management Controls, Design Controls, CAPA, Production and Process Controls, with supporting programs) was the inspection technique developed for the QSR era. FDA has been updating its inspectional approach and associated compliance program documents to align with the QMSR structure. We are not in a position to confirm which compliance program number and revision is current; check FDA's compliance program and inspection guidance pages directly if you are preparing for an inspection.
- MDSAP (Medical Device Single Audit Program) audit reports are accepted by FDA in lieu of routine surveillance inspections under the program's own conditions, but an MDSAP audit or an ISO 13485 certificate does not automatically establish compliance with U.S. legal requirements, and does not displace for-cause, pre-approval or compliance follow-up inspections. Confirm the current program conditions in FDA's MDSAP material.
9. FDA requirements that sit outside Part 820 (unchanged by the QMSR)
The QMSR did not alter these, but they interact closely with your QMS:
| Requirement | Topic |
|---|---|
| 21 CFR Part 803 | Medical Device Reporting (adverse events, malfunctions) |
| 21 CFR Part 806 | Reports of corrections and removals |
| 21 CFR Part 807 | Establishment registration, device listing, premarket notification (510(k)) |
| 21 CFR Part 801 and Part 830 | Labeling and unique device identification (UDI), including GUDID data submission |
| 21 CFR Part 11 | Electronic records and electronic signatures. Applicability depends on the nature and use of the records — for example, whether electronic records are used in place of paper records required by an underlying ("predicate") regulation, or are submitted to or maintained for FDA. Assess applicability system by system rather than assuming it applies to everything electronic. |
10. Frequent misunderstandings
| Misunderstanding | Reality |
|---|---|
| "QMSR just means we follow ISO 13485." | The incorporated ISO 13485:2016 requirements plus the FDA-specific sections of Part 820 (§§820.15, 820.35, 820.45) plus the other FDA requirements in §9 above all apply. |
| "Our ISO 13485 certificate proves QMSR compliance." | Certification can be useful supporting evidence, but it does not substitute for compliance with Part 820, and FDA makes its own determination through its own inspections. |
| "We must delete DHF / DMR / DHR." | Not required. You may keep your existing document names. What matters is that the content satisfies the applicable requirements (e.g. ISO 13485:2016 4.2.3, 7.3.10, 7.5.1) and the FDA-specific record provisions. A documented terminology/requirement mapping is the usual practical solution. |
| "The documentation burden goes down." | The regulation text is shorter, but the incorporated standard adds, for example, a quality manual, medical device files, QMS software validation and risk-based planning. |
| "Design controls are unchanged." | Clause 7.3 expresses planning content, design transfer (7.3.8) and the design and development file (7.3.10) differently from the former §820.30. Re-read your procedures against the clause wording. |
| "Old QSR records are now worthless." | No. Existing records remain your evidence of past activity; the question is whether your current system meets current Part 820. |
11. Practical gap-check list
- Requirement mapping matrix: former QSR section → ISO 13485:2016 clause → FDA-specific Part 820 section → your SOP number.
- Quality manual and medical device files: in place, approved, current, with a documented and justified grouping of devices/device families.
- QMS software validation (ISO 13485:2016 4.1.6): inventory of computerized systems used in the QMS, risk assessment, validation evidence, change control and periodic review.
- Risk management integration (7.1): links from your risk management process into purchasing, production, process validation, CAPA and post-market feedback — not design only.
- Labeling and packaging controls (§820.45) and record content (§820.35), including UDI in the specified complaint and servicing records.
- Complaint → MDR (Part 803) → corrections and removals (Part 806) interfaces: one traceable data flow with documented decision criteria and timeliness.
- Supplier and outsourced process controls (7.4): evaluation criteria, written agreements, change notification, performance monitoring.
- Management review and internal audit records maintained, with a management certification process ready if FDA requests one.
- Inspection readiness: record retrieval mapped to the new Part 820 structure, roles for hosting an inspection, and team familiarity with Form FDA 482/483, the Establishment Inspection Report, and the NAI/VAI/OAI classification outcomes.
12. Primary sources
| Document | Where |
|---|---|
| 21 CFR Part 820 — current text (the QMSR) | eCFR — 21 CFR Part 820 |
| §820.1 Scope · §820.3 Definitions · §820.10 QMS requirements | §820.1 · §820.3 · §820.10 |
| 21 CFR Part 4 — CGMP requirements for combination products | eCFR — 21 CFR Part 4 |
| 21 CFR Part 803 (MDR) · Part 806 · Part 830 (UDI) | Part 803 · Part 806 · Part 830 |
| ISO 13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes | ISO catalogue page |
| ISO 9000:2015 Quality management systems — Fundamentals and vocabulary (source of certain QMSR definitions) | ISO catalogue page |
| FDA final rule Medical Devices; Quality System Regulation Amendments, 89 FR 7496, 2 February 2024, Docket No. FDA-2021-N-0477, effective 2 February 2026 | No link provided, because we have not verified the exact document URL; retrieve the document by this citation from the Federal Register or FDA |
Notes:
※ Section numbers, titles and paragraph designations given above describe the structure of Part 820 as amended; the controlling wording is the current eCFR text, and regulations can be amended further.
※ ISO 13485:2016 and ISO 9000:2015 are copyrighted. Incorporation by reference does not make the standard text freely available, and we cannot reproduce clause text here — only clause numbers and summaries.
※ Statements about FDA's current inspection programs, compliance program numbers and any transition-period enforcement policy are not asserted here as verified facts; confirm the current document title, number, date and status on FDA's website before relying on them.
※ This answer is general regulatory information, not legal advice or a regulatory determination for a specific product. Applicability depends on your device classification, your role (manufacturer, specification developer, contract manufacturer, repackager, importer) and your product type.
※ This answer was generated with AI assistance.
To give you a more targeted comparison, the following scope information would help: your device class and product type, your current QMS basis (ISO 13485-certified, formerly QSR-based, or both), whether combination products are in scope, and whether you are also addressing non-U.S. markets.
Sign in to ask a follow-up. After signing in, return to this question.
Answers provide general information for the stated jurisdiction and reference date. Requirements may change; obtain advice for your particular circumstances.